Novo Nordisk As Stock Price Prediction
| NONOF Stock | USD 109.00 0.70 0.64% |
Oversold Vs Overbought
41
Oversold | Overbought |
Using Novo Nordisk hype-based prediction, you can estimate the value of Novo Nordisk AS from the perspective of Novo Nordisk response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Novo Nordisk to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Novo because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Novo Nordisk after-hype prediction price | USD 109.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Novo |
Novo Nordisk After-Hype Price Prediction Density Analysis
As far as predicting the price of Novo Nordisk at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Novo Nordisk or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Novo Nordisk, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Novo Nordisk Estimiated After-Hype Price Volatility
In the context of predicting Novo Nordisk's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Novo Nordisk's historical news coverage. Novo Nordisk's after-hype downside and upside margins for the prediction period are 106.52 and 111.48, respectively. We have considered Novo Nordisk's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Novo Nordisk is very steady at this time. Analysis and calculation of next after-hype price of Novo Nordisk AS is based on 3 months time horizon.
Novo Nordisk Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Novo Nordisk is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novo Nordisk backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Novo Nordisk, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.35 | 2.48 | 0.00 | 0.01 | 0 Events / Month | 2 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
109.00 | 109.00 | 0.00 |
|
Novo Nordisk Hype Timeline
Novo Nordisk AS is now traded for 109.00. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Novo is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is now at -0.35%. %. The volatility of related hype on Novo Nordisk is about 5904.76%, with the expected price after the next announcement by competition of 108.99. About 39.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.94. Novo Nordisk AS last dividend was issued on the 12th of August 2022. The entity had 5:1 split on the 2nd of January 2014. Assuming the 90 days horizon the next estimated press release will be uncertain. Check out Novo Nordisk Basic Forecasting Models to cross-verify your projections.Novo Nordisk Related Hype Analysis
Having access to credible news sources related to Novo Nordisk's direct competition is more important than ever and may enhance your ability to predict Novo Nordisk's future price movements. Getting to know how Novo Nordisk's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Novo Nordisk may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SBHMY | Sino Biopharmaceutical Ltd | 0.00 | 0 per month | 0.00 | 0.04 | 0.00 | 0.00 | 25.86 | |
| DTCFF | Defence Therapeutics | 0.00 | 0 per month | 0.00 | (0.09) | 0.00 | (2.44) | 25.87 | |
| ALRN | Aileron Therapeutics | (0.28) | 5 per month | 0.00 | (0.05) | 8.06 | (8.77) | 41.47 | |
| ENLV | Enlivex Therapeutics | 0.00 | 4 per month | 3.97 | 0.01 | 10.71 | (6.15) | 35.66 | |
| LVCLF | Living Cell Technologies | 0.00 | 0 per month | 0.00 | (0.06) | 0.00 | 0.00 | 66.02 | |
| MCET | Multicell Techs | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| HESG | Health Sciences Gr | (0.14) | 21 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MYMX | Mymetics Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MRZM | Marizyme | 0.00 | 0 per month | 9.60 | 0.07 | 25.00 | (20.00) | 128.57 | |
| RGBP | Regen BioPharma | 0.00 | 0 per month | 22.54 | 0.14 | 100.00 | (47.83) | 196.39 |
Novo Nordisk Additional Predictive Modules
Most predictive techniques to examine Novo price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Novo using various technical indicators. When you analyze Novo charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Novo Nordisk Predictive Indicators
The successful prediction of Novo Nordisk stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Novo Nordisk AS, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Novo Nordisk based on analysis of Novo Nordisk hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novo Nordisk's related companies.
Story Coverage note for Novo Nordisk
The number of cover stories for Novo Nordisk depends on current market conditions and Novo Nordisk's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Novo Nordisk is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Novo Nordisk's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Novo Nordisk Short Properties
Novo Nordisk's future price predictability will typically decrease when Novo Nordisk's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Novo Nordisk AS often depends not only on the future outlook of the potential Novo Nordisk's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Novo Nordisk's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.2 B |
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |